UW Carbone Experts Present Latest Research at World's Largest Cancer Meeting
Susan Lampert Smith
CHICAGO, Ill. – Research on a DNA vaccine to prevent the return of prostate cancer and a study of gender bias in oncology were among the topics that University of Wisconsin Carbone Cancer Center faculty presented at the world’s largest gathering of cancer specialists.
The American Society of Clinical Oncology (ASCO)’s annual meeting May 31 to June 4 took place at McCormick Place in Chicago. UW Carbone faculty presented research in both poster form and in educational sessions during the event, which drew more than 30,000 cancer specialists from around the world.
Two faculty were featured in “Meet the Professor” sessions for continuing education credits on Friday. Dr. Rebecca Minter, chair of surgery at the University of Wisconsin School of Medicine and Public Health, presented the best evidence for screening high-risk patients for pancreatic cancer. Dr. Toby Campbell, UW Health director of palliative care, delivered a “Primer on Palliative Care Across the Age Spectrum.”
Dr. Ruth O’Regan, an internationally known breast-cancer expert who directs the division of medical oncology/hematology at Carbone, led a discussion on the latest advances in targeted treatment of breast cancer in the enormous D2 lecture hall on Sunday. Also Sunday, Dr. Heather Neuman, a breast cancer surgeon, debated another surgeon on whether all patients with positive nodes need surgery before neoadjuvant therapy.
Monday began with Dr. Ticiana Leal co-chairing a three-hour session on the latest research on metastatic non-small cell lung cancer. She was also co-author on several lung cancer studies that were presented as posters.
Dr. Stephen Rose, professor of obstetrics and gynecology, was senior author of a study presented Monday by former Wisconsin fellow Dr. Shitanshu Uppal, now of the University of Michigan. The retrospective study looked at recurrence rates in patients treated with minimally invasive surgery versus open surgery for cervical cancer, and found slightly higher rates for minimally invasive surgery.
Dr. Hamid Emamekhoo, a specialist in genitourinary cancer, was selected to have his research discussed in the session on genitourinary cancer Monday. Emamekhoo presented data from the ongoing CheckMate 920 clinical trial, which looks at combining two immunotherapy drugs -- nivolumab plus ipilimumab -- in patients whose renal-cell carcinoma has spread to the brain.
Dr. Nataliya Uboha discussed the latest research on gastrointestinal cancers in a “Prevention, Hereditary Genetics and Epidemiology” session that was co-chaired by Carbone’s Dr. Noelle LoConte, on Monday. Dr. Uboha was also the lead author on two clinical trials on immunotherapy and gastrointestinal cancers that were presented in poster sessions on Saturday and Monday.
Dr. Christos Kyriakopoulos is lead author on two clinical studies on advanced prostate cancer that were presented in a poster session on Saturday. During that same session, his colleague, Dr. Glenn Liu, presented results of a phase II clinical trial of a DNA vaccine to prevent prostate-cancer recurrence. That vaccine is based on the research of Carbone colleague Dr. Douglas McNeel, founder of Madison Vaccines, Inc.
An incoming member of UW Carbone Cancer Center, Dr. Narjust Duma, presented research on gender bias in how women oncologists are introduced at scientific meetings. She also did a separate talk on Saturday on creating a mutually respectful workplace. Duma, who joins the Wisconsin faculty in August, is currently chief fellow for hematology/oncology at the Mayo Clinic, where she is a lung-cancer specialist.
Date Published: 05/31/2019